Addendum
Venetoclax (chronic lymphocytic leukaemia; combination with rituximab) - Addendum to Commission A18-81
Report documents
-
Addendum
Venetoclax (chronic lymphocytic leukaemia; combination with rituximab) - Addendum to Commission A18-81
Dossier assessment
Adult patients with chronic lymphocytic leukaemia with at least one prior therapy and without 17p deletion and/or TP53 mutation who are candidates for chemoimmunotherapy
Study MURANO: effects only in favour of venetoclax with rituximab in comparison with bendamustine with rituximab; derivation of an added benefit not possible due to deviation from appropriate comparator therapy, however
Additional information
Federal Joint Committee (G-BA)
2019-05-16 A G-BA decision was published.
Project details
- Project no.
- A19-35
- Commission
- Commission awarded on 09.04.2019 by the Federal Joint Committee (GBA).
- Report type
- Addendum
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Cancer
- Note
-
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
Connected Projects
-
Dossier assessment
Venetoclax (chronic lymphocytic leukaemia) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed